Generated October 13, 2026 at 12:36 PM ET
· Covers October 13 trading day
· 10 of 130 ready 8-Ks selected
· AI-assisted overview
The day's highest-materiality 8-K filings centered on leadership changes, Nasdaq listing compliance, and a cluster of M&A activity. Bausch + Lomb disclosed CEO Brent Saunders' departure effective Oct 12, 2026 and the appointment of Thomas Appio as interim CEO, while Newton Golf and ClearOne each reported Nasdaq staff determinations of non-compliance with the $2,500,000 minimum stockholders' equity requirement and outlined suspension, delisting, or hearing processes. On the deal side, SkyAI announced an intended $3.00-per-share cash tender offer for up to 95% of Sharps Technology's shares and warrants, Skydance reported completing its Warner Bros. Discovery acquisition alongside a warrant dividend and settled note exchange offers, and Bumble agreed to be acquired by Ithaca for $6.05 per share. Corteva and Vylor each filed on a temporary restraining order barring dividends, buybacks and non-ordinary asset sales, which was stayed pending an appellate motion, while BridgeBio and First Tracks Biotherapeutics reported an FDA filing acceptance and Phase 1b clinical results, respectively. Two of the ten cards concern the same Corteva/Vylor litigation and two concern the same Nasdaq equity deficiency rule, so parts of the set are repetitive.
leadership
negative
materiality 0.80
October 13, 2026, 6:09 AM ET
Bausch + Lomb CEO Brent Saunders exits with $75.5M separation; Thomas Appio named interim CEO
- Brent Saunders departs as CEO and board member effective Oct 12, 2026 by mutual agreement; company says exit is not due to any dispute or disagreement.
- Separation Agreement: $75.5M lump-sum cash plus up to $50,000 in attorneys' fees; two years of group health plan participation; no other severance under his 2023 Employment Agreement.
- All of Saunders' outstanding equity awards (options, RSUs, matching RSUs, PSUs, leveraged PSUs, New Hire Grants) were forfeited and cancelled upon signing.
NWTG
Newton Golf Company, Inc.
regulatory
negative
materiality 0.80
October 13, 2026, 8:30 AM ET
Nasdaq staff finds Newton Golf non-compliant; trading suspension set for Oct 15 absent appeal
- Oct 6, 2026 letter: Staff determined Newton Golf did not demonstrate compliance with Nasdaq Listing Rule 5550(b)(1)'s $2,500,000 minimum stockholders' equity requirement.
- Trading of NWTG would be suspended at the open on Oct 15, 2026 unless the company appeals by Oct 13; a Form 25-NSE would then delist and deregister the stock.
- Company got the original deficiency letter April 6, 2026 and submitted compliance plans to Staff on May 21 and Aug 20, 2026, but did not complete the remedial actions.
STSS
Sharps Technology Inc.
M&A
positive
materiality 0.95
October 13, 2026, 9:26 AM ET
SkyAI intends $3.00/share tender offer for up to 95% of shares and warrants, worth up to ~$201M
- SkyAI announced a cash tender offer at $3.00 per share for up to 95% of each class, including common stock and pre-funded/strategic advisor warrants, max aggregate ~$201M.
- Offer expected to begin on/about Oct 15, 2026, last 10 business days, and is conditioned on at least 50% of each class tendered and SOL staying above $100.
- Price represents a 65% premium to SkyAI's Oct 9, 2026 closing price and over 100% premium to its 60-day VWAP, per the press release.
PSKY
Paramount Skydance Corp
M&A
positive
materiality 0.85
October 13, 2026, 8:21 AM ET
Skydance completes Warner Bros. Discovery merger; issues 470.7M warrants at $12, $12.5B notes
- Completed acquisition of Warner Bros. Discovery on Oct 6, 2026 under merger agreement dated Feb 27, 2026; WBD survives as wholly owned Skydance subsidiary.
- Warrant dividend: one warrant per Class B share (record date Oct 5), 470,746,773 warrants issued Oct 13 at $12.00 exercise price, expiring Oct 13, 2036; trade as SKYD WS.
- Exchange Offers settled Oct 9: 99.15% of existing WBD notes tendered; Skydance issued $11.98B and EUR 546.5M of senior secured second lien notes (rates 4.875%-6.350%).
regulatory
negative
materiality 0.80
October 13, 2026, 6:01 AM ET
ClearOne gets Nasdaq delisting notice after missing $2.5M stockholders' equity rule
- Nasdaq Staff determined on Oct 8, 2026 to delist ClearOne (CLRO) after it failed to demonstrate compliance with the $2,500,000 minimum stockholders' equity requirement under Listing Rule 5550(b)(1).
- The company received an initial Nasdaq notice on April 7, 2026, and was given until October 5, 2026 to regain compliance; its May 22, 2026 compliance plan was not completed.
- ClearOne intends to request a hearing before a Nasdaq Hearings Panel by October 15, 2026, which automatically stays suspension or delisting action pending the outcome.
litigation
negative
materiality 0.82
October 13, 2026, 6:30 AM ET
Court TRO bars Corteva dividends, buybacks and non-ordinary asset sales after 15 states sue over Vylor spinoff
- 15 states and one sovereign sued in the U.S. District Court for the Southern District of Indiana on Oct 1, 2026, challenging Corteva's separation from Vylor Inc. and seeking injunctive relief.
- Oct 9 TRO temporarily enjoins Corteva and EIDP from asset disposals outside the ordinary course and bars both companies from paying dividends or repurchasing common shares.
- District Court stayed the Order on Oct 10, 2026 pending Corteva's emergency motion to the Seventh Circuit; the Order is not in effect during appellate review.
BBIO
BridgeBio Pharma, Inc.
regulatory
positive
materiality 0.75
October 13, 2026, 6:01 AM ET
BridgeBio's oral infigratinib NDA accepted by FDA with Priority Review; PDUFA date Feb 4, 2027
- FDA accepted for filing the NDA for oral infigratinib in children with achondroplasia under Priority Review, with a PDUFA target action date of February 4, 2027.
- PROPEL 3 Phase 3 met primary endpoint of annualized height velocity at Week 52: LS mean treatment difference +1.74 cm/yr, mean difference +2.10 cm/yr, p<0.0001; height Z-score also significant.
- First therapy to show statistically significant body-proportionality improvement in a randomized achondroplasia trial (mean difference -0.05, ages 3-8, p<0.05); arm span z-score +0.37 SD, p<0.0001.
litigation
negative
materiality 0.75
October 13, 2026, 8:00 AM ET
Court TRO bars Vylor from dividends or buybacks; 16 plaintiffs challenge Corteva separation
- 15 states plus one sovereign sued in Indiana federal court on Oct 1, 2026, challenging Corteva's separation from Vylor; TRO issued Oct 9.
- Order bars Vylor and Corteva/EIDP from disposing of assets outside ordinary course and from paying dividends or repurchasing shares, absent a court order.
- District court stayed the TRO on Oct 10 pending a Seventh Circuit emergency motion; Vylor, Corteva and EIDP filed notice of appeal the same day.
M&A
positive
materiality 0.90
October 13, 2026, 8:56 AM ET
Bumble to be acquired by Ithaca for $6.05/share, a 138% premium, in $1.3B take-private
- Class A holders get $6.05 cash per share, a 138% premium to the Oct 9, 2026 unaffected close and 119% to the 30-day VWAP.
- Class B shares convert to $0.000001 cash; Opco units receive the $6.05-$0.000001 spread. Options cancelled for no consideration; vested RSUs cashed out.
- Founder/CEO Whitney Wolfe Herd and Beehive Holdings signed a rollover agreement to contribute shares to Oak Topco instead of receiving $6.05; Wolfe Herd recused from board vote.
TRAX
First Tracks Biotherapeutics, Inc.
other material
positive
materiality 0.75
October 13, 2026, 8:32 AM ET
First Tracks' ANB033 hits Phase 1b celiac endpoints; Vh:Cd delta +0.49 (p=0.009), IEL density -20.03 (p<0.001)
- Vh:Cd LS mean change -0.17 on ANB033 vs -0.66 on placebo (placebo-adjusted +0.49, p=0.009); IEL density -1.20 vs +18.83 (-20.03, p<0.001).
- Cohort 1 enrolled 32 patients (17 ANB033, 15 placebo) with a 14-day gluten challenge of 6g daily, about two slices of bread.
- Symptoms suppressed throughout the challenge; 6% of ANB033 patients took rescue GI meds vs 47% on placebo; CDSD benefit significant from day 1.